Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience
Mutations in the <i>KRAS</i> gene are among the most common mutations observed in cancer cells, but they have only recently become an achievable goal for targeted therapies. Two <i>KRAS</i> inhibitors, sotorasib and adagrasib, have recently been approved for the treatment of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/2/325 |
| _version_ | 1797298798228144128 |
|---|---|
| author | Anna K. Rekowska Piotr Rola Agnieszka Kwiatkowska Magdalena Wójcik-Superczyńska Michał Gil Paweł Krawczyk Janusz Milanowski |
| author_facet | Anna K. Rekowska Piotr Rola Agnieszka Kwiatkowska Magdalena Wójcik-Superczyńska Michał Gil Paweł Krawczyk Janusz Milanowski |
| author_sort | Anna K. Rekowska |
| collection | DOAJ |
| description | Mutations in the <i>KRAS</i> gene are among the most common mutations observed in cancer cells, but they have only recently become an achievable goal for targeted therapies. Two <i>KRAS</i> inhibitors, sotorasib and adagrasib, have recently been approved for the treatment of patients with advanced non-small cell lung cancer with the <i>KRAS</i> G12C mutation, while studies on their efficacy are still ongoing. In this work, we comprehensively analyzed <i>RAS</i> gene mutations’ molecular background, mutation testing, KRAS inhibitors’ effectiveness with an emphasis on non-small cell lung cancer, the impact of <i>KRAS</i> mutations on immunotherapy outcomes, and drug resistance problems. We also summarized ongoing trials and analyzed emerging perspectives on targeting KRAS in cancer patients. |
| first_indexed | 2024-03-07T22:41:14Z |
| format | Article |
| id | doaj.art-05ffdb3edf2a4b11b59be44081022dac |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-07T22:41:14Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-05ffdb3edf2a4b11b59be44081022dac2024-02-23T15:08:29ZengMDPI AGBiomedicines2227-90592024-01-0112232510.3390/biomedicines12020325Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center ExperienceAnna K. Rekowska0Piotr Rola1Agnieszka Kwiatkowska2Magdalena Wójcik-Superczyńska3Michał Gil4Paweł Krawczyk5Janusz Milanowski6Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, 20-090 Lublin, PolandMutations in the <i>KRAS</i> gene are among the most common mutations observed in cancer cells, but they have only recently become an achievable goal for targeted therapies. Two <i>KRAS</i> inhibitors, sotorasib and adagrasib, have recently been approved for the treatment of patients with advanced non-small cell lung cancer with the <i>KRAS</i> G12C mutation, while studies on their efficacy are still ongoing. In this work, we comprehensively analyzed <i>RAS</i> gene mutations’ molecular background, mutation testing, KRAS inhibitors’ effectiveness with an emphasis on non-small cell lung cancer, the impact of <i>KRAS</i> mutations on immunotherapy outcomes, and drug resistance problems. We also summarized ongoing trials and analyzed emerging perspectives on targeting KRAS in cancer patients.https://www.mdpi.com/2227-9059/12/2/325non-small cell lung cancer<i>KRAS</i> mutationsKRAS inhibitorsimmunotherapy |
| spellingShingle | Anna K. Rekowska Piotr Rola Agnieszka Kwiatkowska Magdalena Wójcik-Superczyńska Michał Gil Paweł Krawczyk Janusz Milanowski Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience Biomedicines non-small cell lung cancer <i>KRAS</i> mutations KRAS inhibitors immunotherapy |
| title | Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience |
| title_full | Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience |
| title_fullStr | Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience |
| title_full_unstemmed | Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience |
| title_short | Abnormalities in the KRAS Gene and Treatment Options for NSCLC Patients with the G12C Mutation in This Gene—A Literature Review and Single-Center Experience |
| title_sort | abnormalities in the kras gene and treatment options for nsclc patients with the g12c mutation in this gene a literature review and single center experience |
| topic | non-small cell lung cancer <i>KRAS</i> mutations KRAS inhibitors immunotherapy |
| url | https://www.mdpi.com/2227-9059/12/2/325 |
| work_keys_str_mv | AT annakrekowska abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience AT piotrrola abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience AT agnieszkakwiatkowska abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience AT magdalenawojciksuperczynska abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience AT michałgil abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience AT pawełkrawczyk abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience AT januszmilanowski abnormalitiesinthekrasgeneandtreatmentoptionsfornsclcpatientswiththeg12cmutationinthisgenealiteraturereviewandsinglecenterexperience |